牛津大学药物安全博士

Personalised analysis of drug safety and efficacy

Host: University of Oxford (UOXF)

Objectives: To investigate the major differences in the pro-arrhythmic and anti-arrhythmic mechanisms underlying human whole-ventricular EP response to drugs in non-diseased versus diseased conditions. This project will build personalised models of human electro-physiology (in collaboration with F3 and F1), and simulate the activation of the heart to predict the safety and efficacy of pharmacological action in the individual subject. Special emphasis will be given to avoid arrhythmogenic effects, which currently have a huge interest for regulatory bodies (see letter of commitment by FDA). Results will be evaluated in collaboration with F14.

Planned secondment(s):

• Industrial: JAN (P9, pharma industry). For 2M in Y2 to test the ideas in the company’s database of compounds.

• Regulatory experience provided by interactions with the FDA (P4).

• Clinical: co-supervision and interactions within cardiologists at the Oxford JRH (P7).